GlassScriptPhysician profile
Anjali Shetty
NPI 1720303555
$9,653.07
in general payments reported to CMS, 2019-2025
25 companies · $2,367 in 2025
The $2,367 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $669 · 2020: $936 · 2021: $1,005 · 2022: $1,362 · 2023: $1,557 · 2024: $1,758 · 2025: $2,367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,681.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,681.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,057.57 | 2019-2025 | Evenity, Enbrel, Tavneos |
| Abbvie INC. | $1,420.63 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $1,334.83 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Ucb, INC. | $965.34 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $618.79 | 2019-2025 | |
| Lilly USA, LLC | $505.82 | 2019-2025 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $464.91 | 2019-2025 | Orencia |
| Novartis Pharmaceuticals Corporation | $462.08 | 2019-2025 | |
| Genzyme Corporation | $397.27 | 2019-2025 | |
| Radius Health, INC. | $209.82 | 2021-2025 | Tymlos |
| Glaxosmithkline, LLC. | $188.01 | 2020-2025 | Benlysta |
| Alexion Pharmaceuticals, INC. | $183.53 | 2022-2025 | Strensiq |
| Genentech USA, INC. | $174.14 | 2019-2025 | Actemra, Gazyva |
| Sandoz INC. | $128.85 | 2023-2025 | Hyrimoz, Jubbonti |
| Sobi, INC | $104.82 | 2019-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.60 | 2023-2024 | Cyltezo |
| Scilex Pharmaceuticals INC. | $69.10 | 2024-2025 | |
| Fidia Pharma USA INC. | $67.18 | 2019-2025 | Hymovis, Triluron, Hym/Hyn |
| Horizon Therapeutics Plc | $52.71 | 2019-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $44.20 | 2022 | |
| Organon LLC | $36.31 | 2024 | |
| Kiniksa Pharmaceuticals, LTD. | $31.59 | 2023 | Arcalyst |
| Medexus Pharma, INC. | $23.59 | 2019 | |
| Mallinckrodt Enterprises LLC | $22.26 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anjali Shetty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.